Loading
Life sciences · Journal article
Den Open · September 10, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) is an alternative biliary drainage method after failed endoscopic retrograde cholangiopancreatography. Nevertheless, it is associated with adverse events (AEs), including peritonitis and stent migration. The influence of metallic stent (MS) design characteristics, including axial force (AF), on the safety and efficacy of EUS-HGS remains unclear. This multicenter retrospective study included patients with unresectable malignant biliary obstruction who underwent EUS-HGS using either a high-AF MS (Niti-S biliary S-type) or a low-AF MS (EGIS biliary) between January 2019 and December 2022. Propensity score matching was performed in a 1:2 ratio. Outcomes included clinical success, early and late non-recurrent biliary obstruction (non-RBO) AEs, RBO, time to RBO (TRBO), and overall survival (OS). After matching, 27 patients in the high-AF group and 54 in the low-AF group were analyzed. Clinical success, RBO rate, TRBO, OS, and late non-RBO AE rates were similar between groups. However, early non-RBO AEs were more frequent in the high-AF group (37% vs. 13%, p= 0.02). Of the two partially covered MSs evaluated, the EGIS biliary stent demonstrated fewer early non-RBO AEs after EUS-HGS.